Company: BGLC
Filing Date: 2025-08-18
Form Type: 10-Q
Source: 0001477932-25-006023
Chunk: 2

Company: BioNexus Gene Lab Corp
Filing Date: 2025-08-18
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
 no shares outstanding (on a post-reverse stock split basis)*.  12  $17,331,810  $17,332,315 Additional paid in capital      (5,011,891)  (5,011,891)Accumulated deficit      (4,682,119)  (3,442,620)Accumulated other comprehensive losses      (115,763)  (555,000)TOTAL STOCKHOLDERS’ EQUITY      7,522,037   8,322,804              TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY     $9,421,205  $10,433,848 

* Issued and outstanding shares of common stock have been adjusted as below:

1) for the periods prior to April 7, 2025, to reflect the 10-for-1 reverse stock split effected on that date on a retroactive basis as described in Note 12.

2) for the periods prior to July 20, 2023, to reflect the 12-for-1 reverse stock split effected on that date on a retroactive basis as described in Note 12.

See accompanying notes to the condensed consolidated financial statements.

 5Table of Contents

BIONEXUS GENE LAB CORP.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME/(LOSS)  

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024

 (Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

  Three months ended  Six months ended   June 30,  June 30,   2025  2024  2025  2024              REVENUE (Including $16,109 and $7,737 of revenue from related parties for the three month period ended June 30, 2025 and 2024, respectively, and $32,179 and $41,823 of revenue from related parties for the six month period ended June 30, 2025 and 2024, respectively) $2,260,253  $1,974,564  $4,397,328  $4,356,415                COST OF REVENUE (Including $